Novo Nordisk updated investors on Zeus trial outcome. Investors' pre-earnings positioning may also u...
Weight Loss Drug Stocks Slump. What Ozempic Maker Novo Nordisk Said.
Novo Nordisk updated investors on Zeus trial outcome. Investors' pre-earnings positioning may also underlie sliding weight loss drug stocks.
Author: Investor's Business Daily
Read Original Article